awmsg logo



c1 inhibitor (human) (Cinryze®)


Reference No. 3295

Publication date:
19/10/2017


Appraisal information

c1 inhibitor (human) (Cinryze®) 500 international units/ 5ml powder and solvent for solution for injection


Company: Shire Pharmaceuticals Ltd
BNF category: Respiratory system
NMG meeting date: 06/09/2017
AWMSG meeting date: 11/10/2017
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 2117
Ministerial ratification: 18/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

C1 inhibitor (human) (Cinryze®) is recommended as an option for use within NHS Wales for the treatment and pre-procedure prevention of angioedema attacks in adults, adolescents and children (2 years old and above) with hereditary angioedema (HAE); routine prevention of angioedema attacks in adults, adolescents and children (6 years old and above) with severe and recurrent attacks of HAE, who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download